Two Sigma Advisers LP, a prominent hedge fund, has a significant $93.70 million stock position in
Royalty Pharma Plc. The biotech company is fresh from finalizing a significant acquisition and restructuring, which has positioned it as a top-performing pharma stock in 2025. Multiple other major investment firms, including
Raiffeisen Bank International AG and
OMERS ADMINISTRATION Corp, have adjusted their holdings in Royalty Pharma in response to its prosperous market performance. The company is not without its skeptics, with stock holdings recently being trimmed. Royalty Pharma's positive momentum is based on several financial feats, such as an impressive 17% growth in portfolio receipts valued at $839 million. Furthermore, the shareholders have greenlit the internalization of management, which is projected to result in over $1.6 billion in cost savings. Notably, the company’s
Q1 2025 results fell short of EPS estimates. However, its
Q1 sales were in line with expectations, and some analysts consider it to be the most defensive stock amid current market volatility.
Royalty Pharma Stocks News Analytics from Tue, 16 Jun 2020 07:00:00 GMT to Sat, 24 May 2025 10:02:56 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor 2
